Within the Anti-vertigo Drugs market, the type segmentation distinguishes pharmacologic classes that target distinct pathophysiological mechanisms. Antihistamines (e.g., meclizine, dimenhydrinate) dominate volume due to their broad OTC availability and efficacy in suppressing vestibular excitability, accounting for roughly 40 % of sales. Anticholinergics such as scopolamine contribute about 15 % by inhibiting cholinergic transmission in the vestibular nuclei, a niche primarily used in severe vertigo episodes. Calcium‑channel blockers (e.g., flunarizine) represent 12 % and are favored for prophylaxis of vestibular migraine and Meniere’s disease, reflecting higher price points and longer treatment cycles. Benzodiazepines (e.g., diazepam) hold a 10 % share, limited by sedation concerns and regulatory controls. Vestibular suppressants that combine multiple mechanisms, including newer agents like betahistine, capture 18 % of the market, driven by prescription preference in chronic management. The residual 5 % comprises investigational and orphan‑drug categories. This type‑based taxonomy clarifies how each pharmacologic class underpins overall market size and informs revenue allocation across the Anti-vertigo Drugs segmentation.
